Skip to main content

Locally increased uptake of fluorine-18fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors

Publication ,  Journal Article
Marriott, CJC; Thorstad, W; Akabani, G; Brown, MT; McLendon, RE; Hanson, MW; Edward Coleman, R
Published in: Journal of Nuclear Medicine
December 1, 1998

After the intracavitary administration of 131l-labeled monoclonal antibody for treatment of primary brain tumors after surgical resection, a persistent rim of 18F-fluorodeoxyglucose (FDG) accumulation surrounding the cavity can be observed on PET. This rim, although it accumulates more FDG than adjacent normal brain tissue, is not necessarily associated with tumor. In our study, we examine the characteristics of the rim that indicate persistent tumor and tumor progression. Methods: Sequential PET studies obtained after treatment in 10 patients were reviewed and the results correlated with dosimetry and post-treatment histologie diagnoses. Results: The rim of FDG accumulation was seen on the first post-treatment scan obtained 1-3 mo after therapy and persisted unchanged over the 2-26 mo follow-up period. Pathologically, the nonmalignant rim was associated with marked increase of macrophage infiltrates. Modularity of the rim was associated with tumor. Conclusion: Our study demonstrates that a rim of FDG accumulation is seen after intracavitary administration of 131l-labeled monoclonal antibody therapy independent of the presence of malignant disease. Malignant recurrence is suggested by the development of new nodularity in the rim of FDG accumulation.

Duke Scholars

Published In

Journal of Nuclear Medicine

ISSN

0161-5505

Publication Date

December 1, 1998

Volume

39

Issue

8 SUPPL.

Start / End Page

1376 / 1380

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Marriott, C. J. C., Thorstad, W., Akabani, G., Brown, M. T., McLendon, R. E., Hanson, M. W., & Edward Coleman, R. (1998). Locally increased uptake of fluorine-18fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. Journal of Nuclear Medicine, 39(8 SUPPL.), 1376–1380.
Marriott, C. J. C., W. Thorstad, G. Akabani, M. T. Brown, R. E. McLendon, M. W. Hanson, and R. Edward Coleman. “Locally increased uptake of fluorine-18fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.” Journal of Nuclear Medicine 39, no. 8 SUPPL. (December 1, 1998): 1376–80.
Marriott CJC, Thorstad W, Akabani G, Brown MT, McLendon RE, Hanson MW, et al. Locally increased uptake of fluorine-18fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. Journal of Nuclear Medicine. 1998 Dec 1;39(8 SUPPL.):1376–80.
Marriott, C. J. C., et al. “Locally increased uptake of fluorine-18fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.” Journal of Nuclear Medicine, vol. 39, no. 8 SUPPL., Dec. 1998, pp. 1376–80.
Marriott CJC, Thorstad W, Akabani G, Brown MT, McLendon RE, Hanson MW, Edward Coleman R. Locally increased uptake of fluorine-18fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors. Journal of Nuclear Medicine. 1998 Dec 1;39(8 SUPPL.):1376–1380.

Published In

Journal of Nuclear Medicine

ISSN

0161-5505

Publication Date

December 1, 1998

Volume

39

Issue

8 SUPPL.

Start / End Page

1376 / 1380

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 1103 Clinical Sciences